OnCo
Learn & contribute

Completeness: how much of the world is in OnCo

Coverage gauges say whether each record is complete. This page asks the other question: of everything that exists, how much is here? Each row sets an OnCo count against a sourced count of the world, on the same scope, and names what is missing.

Across the 14 scopes with a public list, OnCo holds 1,085 of 2,578 listed items (42.1%). Denominators come from src/data/universe.ts; the lists are refreshed weekly by npm run fetch:universe into src/data/universe-lists/, and the matching lives in src/lib/completeness.ts. “About” marks a denominator that is a round figure, a search hit count, or depends on name matching. A low number is not a failing: OnCo is a curated map, not a registry, and some scopes (every interventional cancer trial, every dictionary term) are shown for scale.

KindScopeIn OnCoOfCoverageSourceMissing
drugsFDA-approved cancer drugs (NCI A to Z list)322382
84.3%
NCI: A to Z List of Cancer Drugs
checked on 2026-09-10
60 listed
cancersCancer types (NCI A to Z list)106128
82.8%
NCI: A to Z List of Cancer Types
checked on 2026-09-10
22 listed
cancersGLOBOCAN 2022 cancer sites2936
80.6%
IARC Global Cancer Observatory: GLOBOCAN 2022
checked on 2026-09-10
7 listed
targetsMolecular targets of approved oncology drugs (ChEMBL)approx.91about 181
50.3%
ChEMBL: mechanism targets of approved drugs with an oncology indication
checked on 2026-09-10
90 listed
trialsInterventional cancer studies on ClinicalTrials.gov42897,105
0.4%
ClinicalTrials.gov: interventional studies, condition 'cancer'
checked on 2026-09-10
96,677 not listed
trialsPhase 3 interventional cancer studies on ClinicalTrials.gov36210,992
3.3%
ClinicalTrials.gov: interventional studies, condition 'cancer'
checked on 2026-09-10
10,630 not listed
trialsRecruiting interventional cancer studies on ClinicalTrials.gov3814,315
0.3%
ClinicalTrials.gov: interventional studies, condition 'cancer'
checked on 2026-09-10
14,277 not listed
companiesIndustry lead sponsors of phase 3 cancer trials (ClinicalTrials.gov)approx.208about 935
22.2%
ClinicalTrials.gov: interventional studies, condition 'cancer'
checked on 2026-09-10
727 listed
companiesCompanies with an FDA oncology approval notification since 2023approx.58about 78
74.4%
FDA Oncology Center of Excellence: approval notifications
checked on 2026-09-10
20 listed
institutionsNCI-designated cancer centres (US)7374
98.6%
NCI: Find a Cancer Center
checked on 2026-09-10
1 listed
institutionsOECI member cancer institutes (Europe and partners)109193
56.5%
OECI: Member Profiles
checked on 2026-09-10
84 listed
institutionsNHS England Cancer Alliances (UK)120
5%
NHS England: Cancer Alliances
checked on 2026-09-10
19 listed
institutionsUICC member organisations (global)approx.557about 1,100
50.6%
UICC: Membership
checked on 2026-09-10
543 not listed
peopleLeaders of OECI member cancer institutesapprox.27about 186
14.5%
OECI: Member Profiles
checked on 2026-09-10
159 listed
peopleDirectors of NCI-designated cancer centresapprox.66about 74
89.2%
NCI: Find a Cancer Center
checked on 2026-09-10
8 not listed
pathwaysKEGG cancer pathway maps728
25%
KEGG PATHWAY: Human Diseases, Cancer
checked on 2026-09-10
21 listed
pathwaysHallmarks of cancer (Hanahan 2022)1414
100%
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery 2022;12(1):31-46
checked on 2026-09-10
0 listed
pathwaysReactome human pathways matching 'cancer'approx.86about 492
17.5%
Reactome: pathways matching 'cancer' (human)
checked on 2026-09-10
406 not listed
journalsMEDLINE-indexed journals under the subject Neoplasms31223
13.9%
NLM Catalog: journals currently indexed for MEDLINE, broad subject term Neoplasms
checked on 2026-09-10
192 listed
key papers100 most-cited oncology works (OpenAlex)9100
9%
OpenAlex: most-cited works, subfield Oncology
checked on 2026-09-10
91 listed
termsNCI Dictionary of Cancer Terms6059,416
6.4%
NCI Dictionary of Cancer Terms
checked on 2026-09-10
8,811 not listed
technologiesTechnologies411no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a
frontsFronts19no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a
pairingsPairings85no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a
roadmapsRoadmaps13no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a
ideasIdeas1,136no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a
bottlenecksBottlenecks45no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a
collectionsCollections110no denominatorOnCo-definedOnCo
checked on 2026-09-10
n/a

Missing, scope by scope

Each list is the source's items that match nothing in OnCo by name, alias, identifier or website. Matching is exact after normalisation, so a listed item can occasionally be present under a name the matcher does not know; if so, add the alias to the record instead.

FDA-approved cancer drugs (NCI A to Z list)

drugs322 of 382 (84.3%)

World: Every link in the A to Z list that points to a drug page; brand-name entries that point to the same page as the generic are folded into one item, so the total is distinct drug pages (single agents and named combinations). NCI: A to Z List of Cancer Drugs, checked on 2026-09-10.

OnCo: Products in OnCo matched to an NCI entry by generic name, brand name, alias or code.

60 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. ABVDAdd this
  2. ABVEAdd this
  3. ABVE-PCAdd this
  4. ACAdd this
  5. AC-TAdd this
  6. ADEAdd this
  7. BEACOPPAdd this
  8. BEPAdd this
  9. BuMelAdd this
  10. CAFAdd this
  11. CARBOPLATIN-TAXOLAdd this
  12. CEMAdd this
  13. CEVAdd this
  14. CHLORAMBUCIL-PREDNISONEAdd this
  15. CHOPAdd this
  16. CMFAdd this
  17. COPDACAdd this
  18. COPPAdd this
  19. COPP-ABVAdd this
  20. CVPAdd this
  21. Eltrombopag Olaminealso Promacta (Eltrombopag Olamine)Add this
  22. Emapalumab-lzsgalso Gamifant (Emapalumab-lzsg)Add this
  23. EPOCHAdd this
  24. FECAdd this
  25. FOLFIRI-BEVACIZUMABAdd this
  26. FOLFIRI-CETUXIMABAdd this
  27. Fostamatinib Disodiumalso Tavalisse (Fostamatinib Disodium)Add this
  28. FU-LVAdd this
  29. GEMCITABINE-OXALIPLATINAdd this
  30. Hyper-CVADAdd this
  31. ICEAdd this
  32. JEBAdd this
  33. Leucovorin CalciumAdd this
  34. MOPPAdd this
  35. MVACAdd this
  36. Niraparib Tosylate Monohydrate and Abiraterone Acetatealso Akeega (Niraparib Tosylate Monohydrate and Abiraterone Acetate)Add this
  37. OEPAAdd this
  38. OFFAdd this
  39. OPPAAdd this
  40. PADAdd this
  41. PCVAdd this
  42. PEBAdd this
  43. Propranolol Hydrochloridealso Hemangeol (Propranolol Hydrochloride)Add this
  44. R-CHOPAdd this
  45. R-CVPAdd this
  46. R-EPOCHAdd this
  47. R-ICEAdd this
  48. Ravulizumab-cwvzalso Ultomiris (Ravulizumab-cwvz)Add this
  49. Ribociclib Succinate and Letrozolealso Kisqali Femara Co-Pack (Ribociclib Succinate and Letrozole)Add this
  50. Rituximab and Hyaluronidase Humanalso Rituxan Hycela (Rituximab and Hyaluronidase Human)Add this
  51. Romiplostimalso Nplate (Romiplostim)Add this
  52. STANFORD VAdd this
  53. TACAdd this
  54. TPFAdd this
  55. Trastuzumab and Hyaluronidase-oyskalso Herceptin Hylecta (Trastuzumab and Hyaluronidase-oysk)Add this
  56. VACAdd this
  57. VAMPAdd this
  58. VeIPAdd this
  59. VIPAdd this
  60. XELIRIAdd this

Cancer types (NCI A to Z list)

cancers106 of 128 (82.8%)

World: Every entry in the 'Find a cancer type' A to Z list (distinct names; several names can share one NCI page). NCI: A to Z List of Cancer Types, checked on 2026-09-10.

OnCo: Cancers in OnCo matched to an NCI entry by name or alias (UK and US spellings treated as equal).

22 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. Basal Cell Carcinoma of the Skin (Skin Cancer)Add this
  2. Bile Duct CancerAdd this
  3. Brain TumorsAdd this
  4. Childhood CancersAdd this
  5. Extragonadal Germ Cell TumorAdd this
  6. Fallopian Tube CancerAdd this
  7. Gastrointestinal Neuroendocrine TumorsAdd this
  8. Gestational Trophoblastic DiseaseAdd this
  9. Intraocular Melanoma (Eye Cancer)Add this
  10. Liver CancerAdd this
  11. Metastatic CancerAdd this
  12. Non-Hodgkin LymphomaAdd this
  13. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)Add this
  14. Primary Peritoneal CancerAdd this
  15. Rectal CancerAdd this
  16. Skin CancerAdd this
  17. Soft Tissue SarcomaAdd this
  18. Squamous Cell Carcinoma of the SkinAdd this
  19. Thymus CancerAdd this
  20. Transitional Cell Cancer of the Renal Pelvis and Ureter (Kidney Cancer)Add this
  21. Ureter and Renal Pelvis, Transitional Cell Cancer (Kidney Cancer)Add this
  22. Young Adults, Cancer inAdd this

GLOBOCAN 2022 cancer sites

cancers29 of 36 (80.6%)

World: The 36 cancer sites GLOBOCAN 2022 estimates (codes 1 to 36 from the GCO metadata API; the aggregate codes 37 to 41 are excluded). IARC Global Cancer Observatory: GLOBOCAN 2022, checked on 2026-09-10.

OnCo: GLOBOCAN sites that at least one OnCo cancer page maps to (src/data/globocan-map.ts).

7 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. GallbladderICD-10 C23Add this
  2. Non-melanoma skin cancerICD-10 C44Add this
  3. Kaposi sarcomaICD-10 C46Add this
  4. VulvaICD-10 C51Add this
  5. VaginaICD-10 C52Add this
  6. PenisICD-10 C60Add this
  7. TestisICD-10 C62Add this

Molecular targets of approved oncology drugs (ChEMBL)

targets91 of about 181 (50.3%)

World: ChEMBL API: drug indications with max_phase_for_ind=4 (approved) whose MeSH heading contains one of Neoplasm, Carcinoma, Leukemia, Lymphoma, Myeloma, Melanoma, Sarcoma, Glioma, Glioblastoma, Tumor, Cancer, Mesothelioma, Blastoma, Adenoma; the distinct parent molecules' mechanisms of action; the distinct targets of those mechanisms, with gene symbols from the target components. Includes non-protein targets (DNA, tubulin) and drugs whose oncology indication is supportive. ChEMBL: mechanism targets of approved drugs with an oncology indication, checked on 2026-09-10.

OnCo: ChEMBL targets whose gene symbol matches an OnCo target's symbol, name or alias.

90 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. DNA43 approved drugs act on it; nucleic-acidAdd this
  2. Tubulin (TUBB4B, TUBB1, TUBA3C, TUBA4A, ...)12 approved drugs act on it; protein complex groupAdd this
  3. Interferon alpha/beta receptor (IFNAR1, IFNAR2)9 approved drugs act on it; protein complexAdd this
  4. Glucocorticoid receptor (NR3C1)7 approved drugs act on it; single proteinAdd this
  5. Granulocyte colony-stimulating factor receptor (CSF3R)6 approved drugs act on it; single proteinAdd this
  6. RNA6 approved drugs act on it; nucleic-acidAdd this
  7. Thymidylate synthase (TYMS)6 approved drugs act on it; single proteinAdd this
  8. Asparagine5 approved drugs act on it; small moleculeAdd this
  9. 26S proteasome (PSMD1, PSMB2, PSMB1, PSMB5, ...)4 approved drugs act on it; protein complexAdd this
  10. Aromatase (CYP19A1)4 approved drugs act on it; single proteinAdd this
  11. DNA topoisomerase II (TOP2A, TOP2B)4 approved drugs act on it; protein familyAdd this
  12. CRL4(CRBN) E3 ubiquitin ligase (CRBN, DDB1, CUL4A, RBX1)3 approved drugs act on it; protein complexAdd this
  13. Dihydrofolate reductase (DHFR)3 approved drugs act on it; single proteinAdd this
  14. Disialoganglioside GD23 approved drugs act on it; small moleculeAdd this
  15. DNA polymerase (alpha/delta/epsilon) (POLA1, POLD4, POLD3, POLD1, ...)3 approved drugs act on it; protein familyAdd this
  16. Elongation factor 2 (EEF2)3 approved drugs act on it; single proteinAdd this
  17. Gonadotropin-releasing hormone receptor (GNRHR)3 approved drugs act on it; single proteinAdd this
  18. Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A)3 approved drugs act on it; single proteinAdd this
  19. Ribonucleoside-diphosphate reductase RR1 (RRM1, RRM2B, RRM2)3 approved drugs act on it; protein complex groupAdd this
  20. 2'-deoxyadenosine2 approved drugs act on it; small moleculeAdd this
  21. 5-hydroxytryptamine receptor 3A (HTR3A)2 approved drugs act on it; single proteinAdd this
  22. Adenosine2 approved drugs act on it; small moleculeAdd this
  23. Angiopoietin-1 receptor (TEK)2 approved drugs act on it; single proteinAdd this
  24. Cannabinoid receptor 1 (CNR1)2 approved drugs act on it; single proteinAdd this
  25. Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1)2 approved drugs act on it; single proteinAdd this
  26. DNA (cytosine-5)-methyltransferase 1 (DNMT1)2 approved drugs act on it; single proteinAdd this
  27. DNA (cytosine-5)-methyltransferase 3A (DNMT3A)2 approved drugs act on it; single proteinAdd this
  28. DNA topoisomerase 1 (TOP1)2 approved drugs act on it; single proteinAdd this
  29. DNA topoisomerase 2-alpha (TOP2A)2 approved drugs act on it; single proteinAdd this
  30. Ephrin type-A receptor 2 (EPHA2)2 approved drugs act on it; single proteinAdd this
  31. Fibroblast growth factor receptor 1 (FGFR1)2 approved drugs act on it; single proteinAdd this
  32. Fibroblast growth factor receptor 3 (FGFR3)2 approved drugs act on it; single proteinAdd this
  33. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD)2 approved drugs act on it; single proteinAdd this
  34. Platelet-derived growth factor receptor beta (PDGFRB)2 approved drugs act on it; single proteinAdd this
  35. Poly [ADP-ribose] polymerase 2 (PARP2)2 approved drugs act on it; single proteinAdd this
  36. Progesterone receptor (PGR)2 approved drugs act on it; single proteinAdd this
  37. Proto-oncogene tyrosine-protein kinase Src (SRC)2 approved drugs act on it; single proteinAdd this
  38. Receptor tyrosine-protein kinase erbB-4 (ERBB4)2 approved drugs act on it; single proteinAdd this
  39. Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)2 approved drugs act on it; single proteinAdd this
  40. Steroid 5-alpha-reductase (SRD5A1, SRD5A2, SRD5A3)2 approved drugs act on it; protein familyAdd this
  41. 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2)1 approved drug act on it; single proteinAdd this
  42. Adenosine deaminase (ADA)1 approved drug act on it; single proteinAdd this
  43. Adrenergic receptor alpha-2 (ADRA2A, ADRA2C, ADRA2B)1 approved drug act on it; protein familyAdd this
  44. ATP-sensitive inward rectifier potassium channel 11 (KCNJ11)1 approved drug act on it; single proteinAdd this
  45. ATP-sensitive inward rectifier potassium channel 8 (KCNJ8)1 approved drug act on it; single proteinAdd this
  46. Cytochrome P450 11B1, mitochondrial (CYP11B1)1 approved drug act on it; single proteinAdd this
  47. D(2) dopamine receptor (DRD2)1 approved drug act on it; single proteinAdd this
  48. Discoidin domain-containing receptor 2 (DDR2)1 approved drug act on it; single proteinAdd this
  49. DNA1 approved drug act on it; nucleic-acidAdd this
  50. Ephrin receptor (EPHA2, EPHB2, EPHA5, EPHA4, ...)1 approved drug act on it; protein familyAdd this
  51. Erythropoietin receptor (EPOR)1 approved drug act on it; single proteinAdd this
  52. Exportin-1 (XPO1)1 approved drug act on it; single proteinAdd this
  53. Gamma-secretase (APH1A, PSENEN, APH1B, PSEN1, ...)1 approved drug act on it; protein complexAdd this
  54. Glutathione reductase, mitochondrial (GSR)1 approved drug act on it; single proteinAdd this
  55. Granulocyte-macrophage colony-stimulating factor receptor (CSF2RA, CSF2RB)1 approved drug act on it; protein complexAdd this
  56. Inosine-5'-monophosphate dehydrogenase (IMPDH) (IMPDH1, IMPDH2)1 approved drug act on it; protein familyAdd this
  57. Insulin-like growth factor 1 receptor (IGF1R)1 approved drug act on it; single proteinAdd this
  58. Interferon gamma receptor (IFNGR2, IFNGR1)1 approved drug act on it; protein complexAdd this
  59. Interleukin-11 receptor subunit alpha (IL11RA)1 approved drug act on it; single proteinAdd this
  60. Iron1 approved drug act on it; metalAdd this
  61. Macrophage-stimulating protein receptor (MST1R)1 approved drug act on it; single proteinAdd this
  62. Melanoma cell1 approved drug act on it; cell-lineAdd this
  63. Mitogen-activated protein kinase 11 (MAPK11)1 approved drug act on it; single proteinAdd this
  64. Mu-type opioid receptor (OPRM1)1 approved drug act on it; single proteinAdd this
  65. Placenta growth factor (PGF)1 approved drug act on it; single proteinAdd this
  66. Prostaglandin G/H synthase 2 (PTGS2)1 approved drug act on it; single proteinAdd this
  67. Prostatic acid phosphatase (ACP3)1 approved drug act on it; single proteinAdd this
  68. Protein kinase C (PKC) (PRKD3, PRKCI, PRKCA, PRKCG, ...)1 approved drug act on it; protein familyAdd this
  69. Protein-tyrosine kinase 6 (PTK6)1 approved drug act on it; single proteinAdd this
  70. RAF proto-oncogene serine/threonine-protein kinase (RAF1)1 approved drug act on it; single proteinAdd this
  71. Retinoic acid receptor (RARG, RARB, RARA)1 approved drug act on it; protein familyAdd this
  72. SLAM family member 7 (SLAMF7)1 approved drug act on it; single proteinAdd this
  73. Sodium channel alpha subunit (SCN1A, SCN5A, SCN4A, SCN7A, ...)1 approved drug act on it; protein familyAdd this
  74. SRC (FYN, SRC, LCK, YES1, ...)1 approved drug act on it; protein familyAdd this
  75. Substance-P receptor (TACR1)1 approved drug act on it; single proteinAdd this
  76. Thioredoxin reductase 1, cytoplasmic (TXNRD1)1 approved drug act on it; single proteinAdd this
  77. Thyroid hormone receptor (THRA, THRB)1 approved drug act on it; protein complexAdd this
  78. Thyrotropin receptor (TSHR)1 approved drug act on it; single proteinAdd this
  79. Toll-like receptor 7 (TLR7)1 approved drug act on it; single proteinAdd this
  80. Trifunctional purine biosynthetic protein adenosine-3 (GART)1 approved drug act on it; single proteinAdd this
  81. Tryptophan 5-hydroxylase (TPH2, TPH1)1 approved drug act on it; protein familyAdd this
  82. Tyrosine-protein kinase FRK (FRK)1 approved drug act on it; single proteinAdd this
  83. Tyrosine-protein kinase HCK (HCK)1 approved drug act on it; single proteinAdd this
  84. Tyrosine-protein kinase Lyn (LYN)1 approved drug act on it; single proteinAdd this
  85. Tyrosine-protein kinase receptor UFO (AXL)1 approved drug act on it; single proteinAdd this
  86. Uric acid1 approved drug act on it; small moleculeAdd this
  87. Vascular endothelial growth factor receptor 1 (FLT1)1 approved drug act on it; single proteinAdd this
  88. Vascular endothelial growth factor receptor 3 (FLT4)1 approved drug act on it; single proteinAdd this
  89. Voltage-gated potassium channel (KCNQ1, KCND3, KCNH2, KCNA2, ...)1 approved drug act on it; protein familyAdd this
  90. Xanthine dehydrogenase/oxidase (XDH)1 approved drug act on it; single proteinAdd this

Interventional cancer studies on ClinicalTrials.gov

trials428 of 97,105 (0.4%)

World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-10.

OnCo: OnCo trials with an NCT id.

The source publishes a total, not a list, so the gap (96,677) cannot be itemised here. Propose an addition through the new-object form.

Phase 3 interventional cancer studies on ClinicalTrials.gov

trials362 of 10,992 (3.3%)

World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-10.

OnCo: OnCo trials with an NCT id and phase 3 or 2/3.

The source publishes a total, not a list, so the gap (10,630) cannot be itemised here. Propose an addition through the new-object form.

Recruiting interventional cancer studies on ClinicalTrials.gov

trials38 of 14,315 (0.3%)

World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-10.

OnCo: OnCo trials with an NCT id whose status is recruiting or active.

The source publishes a total, not a list, so the gap (14,277) cannot be itemised here. Propose an addition through the new-object form.

Industry lead sponsors of phase 3 cancer trials (ClinicalTrials.gov)

companies208 of about 935 (22.2%)

World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-10.

OnCo: Sponsor names matched to an OnCo company by name or alias after removing corporate suffixes; subsidiaries listed under their own name count as separate sponsors.

727 missing, first 150 shown. Each “Add this” opens the new-object issue form, prefilled.
  1. Celgene50 phase 3 cancer trials as lead sponsorAdd this
  2. Qilu Pharmaceutical Co., Ltd.34 phase 3 cancer trials as lead sponsorAdd this
  3. Sichuan Baili Pharmaceutical Co., Ltd.33 phase 3 cancer trials as lead sponsorAdd this
  4. Suzhou Suncadia Biopharmaceuticals Co., Ltd.25 phase 3 cancer trials as lead sponsorAdd this
  5. BeiGene19 phase 3 cancer trials as lead sponsorAdd this
  6. Spectrum Pharmaceuticals, Inc18 phase 3 cancer trials as lead sponsorAdd this
  7. Biocad16 phase 3 cancer trials as lead sponsorAdd this
  8. Alexion Pharmaceuticals, Inc.15 phase 3 cancer trials as lead sponsorAdd this
  9. Endo USA Inc., a Keenova Therapeutics Company15 phase 3 cancer trials as lead sponsorAdd this
  10. Shanghai JMT-Bio Inc.15 phase 3 cancer trials as lead sponsorAdd this
  11. Genzyme, a Sanofi Company14 phase 3 cancer trials as lead sponsorAdd this
  12. AB Science13 phase 3 cancer trials as lead sponsorAdd this
  13. CSPC ZhongQi Pharmaceutical Technology Co., Ltd.13 phase 3 cancer trials as lead sponsorAdd this
  14. CTI BioPharma13 phase 3 cancer trials as lead sponsorAdd this
  15. Millennium Pharmaceuticals, Inc.13 phase 3 cancer trials as lead sponsorAdd this
  16. UCB Biopharma SRL13 phase 3 cancer trials as lead sponsorAdd this
  17. CSPC Megalith Biopharmaceutical Co.,Ltd.11 phase 3 cancer trials as lead sponsorAdd this
  18. EMD Serono Research & Development Institute, Inc.11 phase 3 cancer trials as lead sponsorAdd this
  19. Galderma R&D11 phase 3 cancer trials as lead sponsorAdd this
  20. Hutchison Medipharma Limited11 phase 3 cancer trials as lead sponsorAdd this
  21. LEO Pharma11 phase 3 cancer trials as lead sponsorAdd this
  22. Sinocelltech Ltd.11 phase 3 cancer trials as lead sponsorAdd this
  23. argenx10 phase 3 cancer trials as lead sponsorAdd this
  24. Astex Pharmaceuticals, Inc.9 phase 3 cancer trials as lead sponsorAdd this
  25. Pharmacyclics LLC.9 phase 3 cancer trials as lead sponsorAdd this
  26. Acerta Pharma BV7 phase 3 cancer trials as lead sponsorAdd this
  27. Actavis Inc.7 phase 3 cancer trials as lead sponsorAdd this
  28. Almirall, S.A.7 phase 3 cancer trials as lead sponsorAdd this
  29. Alza Corporation, DE, USA7 phase 3 cancer trials as lead sponsorAdd this
  30. Celgene Corporation7 phase 3 cancer trials as lead sponsorAdd this
  31. Celltrion7 phase 3 cancer trials as lead sponsorAdd this
  32. Cephalon7 phase 3 cancer trials as lead sponsorAdd this
  33. Jiangsu Simcere Pharmaceutical Co., Ltd.7 phase 3 cancer trials as lead sponsorAdd this
  34. Nektar Therapeutics7 phase 3 cancer trials as lead sponsorAdd this
  35. Repros Therapeutics Inc.7 phase 3 cancer trials as lead sponsorAdd this
  36. Shanghai Bovax Biotechnology Co., Ltd.7 phase 3 cancer trials as lead sponsorAdd this
  37. UroGen Pharma Ltd.7 phase 3 cancer trials as lead sponsorAdd this
  38. Changchun GeneScience Pharmaceutical Co., Ltd.6 phase 3 cancer trials as lead sponsorAdd this
  39. Eurofarma Laboratorios S.A.6 phase 3 cancer trials as lead sponsorAdd this
  40. Genta Incorporated6 phase 3 cancer trials as lead sponsorAdd this
  41. Graceway Pharmaceuticals, LLC6 phase 3 cancer trials as lead sponsorAdd this
  42. Kythera Biopharmaceuticals6 phase 3 cancer trials as lead sponsorAdd this
  43. Luye Pharma Group Ltd.6 phase 3 cancer trials as lead sponsorAdd this
  44. Mabwell (Shanghai) Bioscience Co., Ltd.6 phase 3 cancer trials as lead sponsorAdd this
  45. Mirati Therapeutics Inc.6 phase 3 cancer trials as lead sponsorAdd this
  46. R-Pharm6 phase 3 cancer trials as lead sponsorAdd this
  47. Achieve Life Sciences5 phase 3 cancer trials as lead sponsorAdd this
  48. Bio-Thera Solutions5 phase 3 cancer trials as lead sponsorAdd this
  49. Biogen5 phase 3 cancer trials as lead sponsorAdd this
  50. Dendreon5 phase 3 cancer trials as lead sponsorAdd this
  51. Foresee Pharmaceuticals Co., Ltd.5 phase 3 cancer trials as lead sponsorAdd this
  52. GTx5 phase 3 cancer trials as lead sponsorAdd this
  53. Natureceuticals Sdn Bhd5 phase 3 cancer trials as lead sponsorAdd this
  54. Nobelpharma5 phase 3 cancer trials as lead sponsorAdd this
  55. Peplin5 phase 3 cancer trials as lead sponsorAdd this
  56. pharmaand GmbH5 phase 3 cancer trials as lead sponsorAdd this
  57. Photocure5 phase 3 cancer trials as lead sponsorAdd this
  58. SecuraBio5 phase 3 cancer trials as lead sponsorAdd this
  59. Tesaro, Inc.5 phase 3 cancer trials as lead sponsorAdd this
  60. UCB Pharma5 phase 3 cancer trials as lead sponsorAdd this
  61. Zai Lab (Shanghai) Co., Ltd.5 phase 3 cancer trials as lead sponsorAdd this
  62. AEterna Zentaris4 phase 3 cancer trials as lead sponsorAdd this
  63. Agennix4 phase 3 cancer trials as lead sponsorAdd this
  64. Agenus Inc.4 phase 3 cancer trials as lead sponsorAdd this
  65. American Regent, Inc.4 phase 3 cancer trials as lead sponsorAdd this
  66. AOP Orphan Pharmaceuticals AG4 phase 3 cancer trials as lead sponsorAdd this
  67. Aragon Pharmaceuticals, Inc.4 phase 3 cancer trials as lead sponsorAdd this
  68. Ascentage Pharma Group Inc.4 phase 3 cancer trials as lead sponsorAdd this
  69. Beijing Biostar Pharmaceuticals Co., Ltd.4 phase 3 cancer trials as lead sponsorAdd this
  70. BeyondSpring Pharmaceuticals Inc.4 phase 3 cancer trials as lead sponsorAdd this
  71. Catalyst Pharmaceuticals, Inc.4 phase 3 cancer trials as lead sponsorAdd this
  72. Delcath Systems Inc.4 phase 3 cancer trials as lead sponsorAdd this
  73. Dizal Pharmaceuticals4 phase 3 cancer trials as lead sponsorAdd this
  74. EMD Serono4 phase 3 cancer trials as lead sponsorAdd this
  75. HTA Co., Ltd.4 phase 3 cancer trials as lead sponsorAdd this
  76. Inovio Pharmaceuticals4 phase 3 cancer trials as lead sponsorAdd this
  77. INSYS Therapeutics Inc4 phase 3 cancer trials as lead sponsorAdd this
  78. Intarcia Therapeutics4 phase 3 cancer trials as lead sponsorAdd this
  79. Lee's Pharmaceutical Limited4 phase 3 cancer trials as lead sponsorAdd this
  80. mAbxience Research S.L.4 phase 3 cancer trials as lead sponsorAdd this
  81. Neovii Biotech4 phase 3 cancer trials as lead sponsorAdd this
  82. Norgine4 phase 3 cancer trials as lead sponsorAdd this
  83. Nuvation Bio Inc.4 phase 3 cancer trials as lead sponsorAdd this
  84. Nycomed4 phase 3 cancer trials as lead sponsorAdd this
  85. PharmaEssentia4 phase 3 cancer trials as lead sponsorAdd this
  86. Polaris Group4 phase 3 cancer trials as lead sponsorAdd this
  87. PregLem SA4 phase 3 cancer trials as lead sponsorAdd this
  88. Sequus Pharmaceuticals4 phase 3 cancer trials as lead sponsorAdd this
  89. Shandong New Time Pharmaceutical Co., LTD4 phase 3 cancer trials as lead sponsorAdd this
  90. Shandong Suncadia Medicine Co., Ltd.4 phase 3 cancer trials as lead sponsorAdd this
  91. Sol-Gel Technologies, Ltd.4 phase 3 cancer trials as lead sponsorAdd this
  92. Taizhou Hanzhong biomedical co. LTD4 phase 3 cancer trials as lead sponsorAdd this
  93. Telik4 phase 3 cancer trials as lead sponsorAdd this
  94. Teva Branded Pharmaceutical Products R&D, Inc.4 phase 3 cancer trials as lead sponsorAdd this
  95. TG Therapeutics, Inc.4 phase 3 cancer trials as lead sponsorAdd this
  96. ABX advanced biochemical compounds GmbH3 phase 3 cancer trials as lead sponsorAdd this
  97. Aclaris Therapeutics, Inc.3 phase 3 cancer trials as lead sponsorAdd this
  98. AGO Research GmbH3 phase 3 cancer trials as lead sponsorAdd this
  99. Archimedes Development Ltd3 phase 3 cancer trials as lead sponsorAdd this
  100. Arcus Biosciences, Inc.3 phase 3 cancer trials as lead sponsorAdd this
  101. Ariad Pharmaceuticals3 phase 3 cancer trials as lead sponsorAdd this
  102. BeBetter Med Inc3 phase 3 cancer trials as lead sponsorAdd this
  103. Beijing Health Guard Biotechnology, Inc3 phase 3 cancer trials as lead sponsorAdd this
  104. Beijing Pearl Biotechnology Limited Liability Company3 phase 3 cancer trials as lead sponsorAdd this
  105. BioDelivery Sciences International3 phase 3 cancer trials as lead sponsorAdd this
  106. Bioniche Life Sciences Inc.3 phase 3 cancer trials as lead sponsorAdd this
  107. BioNumerik Pharmaceuticals, Inc.3 phase 3 cancer trials as lead sponsorAdd this
  108. BioVex Limited3 phase 3 cancer trials as lead sponsorAdd this
  109. Cancer Advances Inc.3 phase 3 cancer trials as lead sponsorAdd this
  110. Catalysis SL3 phase 3 cancer trials as lead sponsorAdd this
  111. Celtic Pharma Development Services3 phase 3 cancer trials as lead sponsorAdd this
  112. Chugai Pharmaceutical3 phase 3 cancer trials as lead sponsorAdd this
  113. Cordgenics, LLC3 phase 3 cancer trials as lead sponsorAdd this
  114. Dexa Medica Group3 phase 3 cancer trials as lead sponsorAdd this
  115. ERYtech Pharma3 phase 3 cancer trials as lead sponsorAdd this
  116. GC Cell Corporation3 phase 3 cancer trials as lead sponsorAdd this
  117. Genor Biopharma Co., Ltd.3 phase 3 cancer trials as lead sponsorAdd this
  118. GP-Pharm3 phase 3 cancer trials as lead sponsorAdd this
  119. Grünenthal GmbH3 phase 3 cancer trials as lead sponsorAdd this
  120. Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair3 phase 3 cancer trials as lead sponsorAdd this
  121. Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair3 phase 3 cancer trials as lead sponsorAdd this
  122. Heidelberg Pharma AG3 phase 3 cancer trials as lead sponsorAdd this
  123. Il-Yang Pharm. Co., Ltd.3 phase 3 cancer trials as lead sponsorAdd this
  124. Imunon3 phase 3 cancer trials as lead sponsorAdd this
  125. iOMEDICO AG3 phase 3 cancer trials as lead sponsorAdd this
  126. Janssen Pharmaceutical K.K.3 phase 3 cancer trials as lead sponsorAdd this
  127. Janssen-Cilag G.m.b.H3 phase 3 cancer trials as lead sponsorAdd this
  128. Juno Therapeutics, Inc., a Bristol-Myers Squibb Company3 phase 3 cancer trials as lead sponsorAdd this
  129. Lepu Biopharma Co., Ltd.3 phase 3 cancer trials as lead sponsorAdd this
  130. Mateon Therapeutics3 phase 3 cancer trials as lead sponsorAdd this
  131. MEDA Pharma GmbH & Co. KG3 phase 3 cancer trials as lead sponsorAdd this
  132. medac GmbH3 phase 3 cancer trials as lead sponsorAdd this
  133. Medical Enterprises Europe B.V.3 phase 3 cancer trials as lead sponsorAdd this
  134. Nanjing Sanhome Pharmaceutical, Co., Ltd.3 phase 3 cancer trials as lead sponsorAdd this
  135. Navidea Biopharmaceuticals3 phase 3 cancer trials as lead sponsorAdd this
  136. NewLink Genetics Corporation3 phase 3 cancer trials as lead sponsorAdd this
  137. Norroy Bioscience Co., LTD3 phase 3 cancer trials as lead sponsorAdd this
  138. Ortho Biotech Products, L.P.3 phase 3 cancer trials as lead sponsorAdd this
  139. OSI Pharmaceuticals3 phase 3 cancer trials as lead sponsorAdd this
  140. Philogen S.p.A.3 phase 3 cancer trials as lead sponsorAdd this
  141. QLT Inc.3 phase 3 cancer trials as lead sponsorAdd this
  142. Relmada Therapeutics, Inc.3 phase 3 cancer trials as lead sponsorAdd this
  143. S.L.A. Pharma AG3 phase 3 cancer trials as lead sponsorAdd this
  144. Samyang Biopharmaceuticals Corporation3 phase 3 cancer trials as lead sponsorAdd this
  145. Shandong Lanjin Pharmaceuticals Co.,Ltd3 phase 3 cancer trials as lead sponsorAdd this
  146. Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.3 phase 3 cancer trials as lead sponsorAdd this
  147. Shanghai Institute Of Biological Products3 phase 3 cancer trials as lead sponsorAdd this
  148. Shanghai Shengdi Pharmaceutical Co., Ltd3 phase 3 cancer trials as lead sponsorAdd this
  149. Shanghai Yizhong Pharmaceutical Co., Ltd.3 phase 3 cancer trials as lead sponsorAdd this
  150. Shanghai Zerun Biotechnology Co.,Ltd3 phase 3 cancer trials as lead sponsorAdd this

The full list is in src/data/universe-lists/ctgov-oncology.json.

Companies with an FDA oncology approval notification since 2023

companies58 of about 78 (74.4%)

World: Sponsor named in brackets in each FDA OCE oncology approval notification on the current page, grouped after removing corporate suffixes. Covers the notifications the page still lists (see window), so it is a floor for 'companies with a recent FDA oncology approval'. FDA Oncology Center of Excellence: approval notifications, checked on 2026-09-10.

OnCo: Sponsors named in FDA OCE notifications matched to an OnCo company by name or alias.

20 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. Juno Therapeutics, Inc.2 FDA oncology approval notifications, 2024 to 2024Add this
  2. Altor BioScience, LLC1 FDA oncology approval notification, 2024 to 2024Add this
  3. BeiGene USA, Inc.1 FDA oncology approval notification, 2024 to 2024Add this
  4. Checkpoint Therapeutics, Inc.1 FDA oncology approval notification, 2024 to 2024Add this
  5. Coherus BioSciences, Inc.1 FDA oncology approval notification, 2023 to 2023Add this
  6. Dizal (Jiangsu) Pharmaceutical Co., Ltd.1 FDA oncology approval notification, 2025 to 2025Add this
  7. EMD Serono, Inc.1 FDA oncology approval notification, 2024 to 2024Add this
  8. Gamida Cell Ltd.1 FDA oncology approval notification, 2023 to 2023Add this
  9. Geron Corporation1 FDA oncology approval notification, 2024 to 2024Add this
  10. Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1 FDA oncology approval notification, 2025 to 2025Add this
  11. medac GmbH1 FDA oncology approval notification, 2025 to 2025Add this
  12. melphalan for Injection/Hepatic Delivery System1 FDA oncology approval notification, 2023 to 2023Add this
  13. Mesoblast, Inc.1 FDA oncology approval notification, 2024 to 2024Add this
  14. Mirati Therapeutics, Inc.1 FDA oncology approval notification, 2024 to 2024Add this
  15. Nuvation Bio Inc.1 FDA oncology approval notification, 2025 to 2025Add this
  16. Partner Therapeutics, Inc.1 FDA oncology approval notification, 2026 to 2026Add this
  17. pharmaand GmbH1 FDA oncology approval notification, 2025 to 2025Add this
  18. UroGen Pharma1 FDA oncology approval notification, 2025 to 2025Add this
  19. USWM, LLC1 FDA oncology approval notification, 2023 to 2023Add this
  20. Xcovery Holdings, Inc.1 FDA oncology approval notification, 2024 to 2024Add this

NCI-designated cancer centres (US)

institutions73 of 74 (98.6%)

World: Every centre profile linked from the NCI 'Find a Cancer Center' page (one entry per centre, even when a centre is listed in several states); the website comes from each profile page. NCI: Find a Cancer Center, checked on 2026-09-10.

OnCo: NCI centres matched to an OnCo institution by website domain or name.

1 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. Mount Sinai Tisch Cancer CenterAdd this

OECI member cancer institutes (Europe and partners)

institutions109 of 193 (56.5%)

World: Every member profile on the Organisation of European Cancer Institutes member list (full, associate and corresponding members), with the leaders named on each profile. OECI: Member Profiles, checked on 2026-09-10.

OnCo: OECI members matched to an OnCo institution by website domain or name.

84 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. University Hospital Center "Mother Teresa"Albania; associate memberAdd this
  2. مركز مكافحة السرطان البليدة المؤسسة الاستشفائية المتخصصة بمكافحة السرطان البليدةAlgeria; associate memberAdd this
  3. Brussels Cancer Centre - Centre du Cancer BruxellesBelgium; full memberAdd this
  4. Многопрофилна Болница за Активно Лечение Сърце и Мозък Плевен,БългарияBulgaria; full memberAdd this
  5. Съвместна онкологична национална мрежа (СОНМ)Bulgaria; associate memberAdd this
  6. Jinshazhou Hospital of Guangzhou University of Chinese MedicineChina; associate memberAdd this
  7. University Hospital for Tumors, Sestre milosrdnice University Hospital CentreCroatia; full memberAdd this
  8. Koalicija udruga u zdravstvu KUZCroatia; associate memberAdd this
  9. German Oncology CenterCyprus; full memberAdd this
  10. Ογκολογικό Κέντρο Τράπεζας ΚύπρουCyprus; full memberAdd this
  11. Motol University Hospital (MUH)Czech Republic; full memberAdd this
  12. Institute of Biostatistics and Analyses,Faculty of Medicine and Faculty of Science, Masaryk UniversityCzech Republic; associate memberAdd this
  13. Copenhagen Comprehensive Cancer Center (CCCC) Departement for cancer treatment, Herlev and Gentofte HospitalDenmark; full memberAdd this
  14. Odense University HospitalDenmark; full memberAdd this
  15. Aalborg University HospitalDenmark; full memberAdd this
  16. Zealand University HospitalDenmark; full memberAdd this
  17. North Estonia Medical CentreEstonia; full memberAdd this
  18. East Tallinn Central HospitalEstonia; full memberAdd this
  19. Oulu University HospitalFinland; full memberAdd this
  20. Finnish Cancer Center - FICANFinland; full memberAdd this
  21. Integrated Center for OncologyFrance; full memberAdd this
  22. Assistance Publique – Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université (IUC APHP.SU)France; linked institutionAdd this
  23. Institut GodinotFrance; full memberAdd this
  24. Georges-François Leclerc Cancer CenterFrance; full memberAdd this
  25. Institut de Cancérologie de LorraineFrance; full memberAdd this
  26. Institut StraussFrance; full memberAdd this
  27. Institut Sainte CatherineFrance; associate memberAdd this
  28. University Hospitals of MarseilleFrance; full memberAdd this
  29. National Cancer Center DresdenGermany; full memberAdd this
  30. Charité Comprehensive Cancer CenterGermany; full memberAdd this
  31. Γενικο Αντικαρκινικο Νοσοκομειο Πειραια ΜεταξαGreece; full memberAdd this
  32. Ελληνικη Ομοσπονδια Καρκινου - ΕΛΛΟΚGreece; associate memberAdd this
  33. Országos Korányi Pulmonológiai IntézetHungary; full memberAdd this
  34. Landspitali University HospitalIceland; full memberAdd this
  35. Mater Private NetworkIreland; full memberAdd this
  36. The Mater Misericordiae University HospitalIreland; full memberAdd this
  37. Mid-Western Cancer CentreIreland; full memberAdd this
  38. University Hospital WaterfordIreland; full memberAdd this
  39. INOC - Istituto Nazionale Oncologico CandioloItaly; full memberAdd this
  40. Mediterranean Institute of OncologyItaly; full memberAdd this
  41. Fondazione PoliambulanzaItaly; full memberAdd this
  42. Fondazione IRCCS Policlinico San MatteoItaly; associate memberAdd this
  43. Italian Federation of Voluntary Associations in OncologyItaly; associate memberAdd this
  44. Fondazione The Bridge ETSItaly; associate memberAdd this
  45. Pauls Stradins Clinical University Hospital (PSCUH)Latvia; full memberAdd this
  46. Vilniaus universiteto ligoninė Santaros klinikosLithuania; full memberAdd this
  47. Lietuvos sveikatos mokslų universiteto ligoninė Kauno klinikosLithuania; full memberAdd this
  48. Klaipėda University HospitalLithuania; full memberAdd this
  49. Public Health Institution Oncological InstituteMoldova; associate memberAdd this
  50. PHI University Clinic for Radiotherapy and Oncology SkopjeNorth Macedonia; associate memberAdd this
  51. Helse Bergen - Haukeland University HospitalNorway; full memberAdd this
  52. Akershus University Hospital TrustNorway; full memberAdd this
  53. Clínica Oncosalud - AUNAPeru; associate memberAdd this
  54. Maria Sklodowska- Curie National Research Institute of OncologyPoland; full memberAdd this
  55. Maria Skłodowska-Curie National Institute of Oncology National Research Institute Gliwice BranchPoland; linked institutionAdd this
  56. Institute of Mother and ChildPoland; full memberAdd this
  57. University Clinical Center (UCK) of Medical University of GdanskPoland; full memberAdd this
  58. Polish Mothers Memorial Hospital Research InstitutePoland; full memberAdd this
  59. AidPort Clinical Trial HospitalPoland; associate memberAdd this
  60. Iași Regional Oncology InstituteRomania; associate memberAdd this
  61. Cancer Free Future AssociationRomania; associate memberAdd this
  62. Государственное автономное учреждение здравоохранения "Республиканский клинический онкологический диспансер министерства здравоохранения Республики Татарстан"Russian Federation; associate memberAdd this
  63. Федеральное государственное бюджетное научное учреждение «Российский научный онкологический центр им. Н.Н.Блохина»Russian Federation; associate memberAdd this
  64. Государственный научно-исследовательский центр радиологииRussian Federation; associate memberAdd this
  65. Oncology Institute of VojvodinaSerbia; associate memberAdd this
  66. Biomedical Research Center of the Slovak Academy of SciencesSlovakia; associate memberAdd this
  67. Vall d’Hebron Barcelona Hospital CampusSpain; full memberAdd this
  68. Southern Catalonia Oncology Institute University Hospital Sant Joan of ReusSpain; full memberAdd this
  69. Centro Integral Oncológico Clara CampalSpain; full memberAdd this
  70. Campus Sant Pau – PuigvertSpain; associate memberAdd this
  71. Hospital Universitario Virgen de la VictoriaSpain; full memberAdd this
  72. Doctor Peset University HospitalSpain; full memberAdd this
  73. Spanish Association Against CancerSpain; associate memberAdd this
  74. Karolinska Comprehensive Cancer CenterSweden; full memberAdd this
  75. Örebro Comprehensive Cancer CentreSweden; full memberAdd this
  76. University Hospital of UmeåSweden; associate memberAdd this
  77. Stockholm Gotland Comprehensive Cancer Network – SGCCNSweden; linked institutionAdd this
  78. Capio Saint Göran's HospitalSweden; full memberAdd this
  79. Swedish Network Against Cancer (NMC)Sweden; associate memberAdd this
  80. The Aga Khan Hospital, Dar es SalaamTanzania; associate memberAdd this
  81. Netherlands Comprehensive Cancer OrganisationThe Netherlands; full memberAdd this
  82. Dokuz Eylul University Instıtute of OncologyTurkey; associate memberAdd this
  83. Türkiye Cancer Institute-TKETurkey; associate memberAdd this
  84. RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR)Ukraine; associate memberAdd this

NHS England Cancer Alliances (UK)

institutions1 of 20 (5%)

World: The numbered list of Cancer Alliances under 'Map of Cancer Alliances in England' on the NHS England page. NHS England: Cancer Alliances, checked on 2026-09-10.

OnCo: Cancer Alliances matched to an OnCo institution by website domain or name.

19 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. Northern Cancer AllianceAdd this
  2. Lancashire and South Cumbria Cancer AllianceAdd this
  3. West Yorkshire and Harrogate Cancer AllianceAdd this
  4. Humber & North Yorkshire Cancer AllianceAdd this
  5. Cheshire and Merseyside Cancer AllianceAdd this
  6. Greater Manchester Cancer AllianceAdd this
  7. South Yorkshire and Bassetlaw Cancer AllianceAdd this
  8. West Midlands Cancer AllianceAdd this
  9. East Midlands Cancer AllianceAdd this
  10. East of England Cancer AllianceAdd this
  11. North Central London Cancer AllianceAdd this
  12. North East London Cancer AllianceAdd this
  13. South East London Cancer AllianceAdd this
  14. Kent and Medway Cancer AllianceAdd this
  15. Surrey and Sussex Cancer AllianceAdd this
  16. Wessex Cancer AllianceAdd this
  17. Thames Valley Cancer AllianceAdd this
  18. Somerset, Wiltshire, Avon and Gloucestershire Cancer AllianceAdd this
  19. Peninsula Cancer AllianceAdd this

UICC member organisations (global)

institutions557 of about 1,100 (50.6%)

World: The member-organisation count stated on the UICC membership page (a round figure published by UICC, so approximate). UICC: Membership, checked on 2026-09-10.

OnCo: All institutions in OnCo (membership is not verified per record, so this is an upper bound on coverage).

The source publishes a total, not a list, so the gap (543) cannot be itemised here. Propose an addition through the new-object form.

Leaders of OECI member cancer institutes

people27 of about 186 (14.5%)

World: The first person named under the leadership heading of each OECI member profile (director, CEO or equivalent); members with no leader listed are excluded. OECI: Member Profiles, checked on 2026-09-10.

OnCo: Leaders matched to an OnCo person by name after removing titles.

159 missing, first 150 shown. Each “Add this” opens the new-object issue form, prefilled.
  1. Adda Bounedjarمركز مكافحة السرطان البليدة المؤسسة الاستشفائية المتخصصة بمكافحة السرطان البليدة, AlgeriaAdd this
  2. Shahrokh ShariatComprehensive Cancer Center Vienna, AustriaAdd this
  3. Sacha GougnardInstitut Jules Bordet (IJB), BelgiumAdd this
  4. Inge BuyseKortrijk Cancer Centre az groeninge, BelgiumAdd this
  5. Mark De RidderBrussels Cancer Centre - Centre du Cancer Bruxelles, BelgiumAdd this
  6. Frank VermassenUniversity Hospital Ghent Cancer Centre, BelgiumAdd this
  7. Philippe LeroyKing Albert II Cancer Institute, BelgiumAdd this
  8. Victor Piana de AndradeA.C. Camargo Cancer Center, BrazilAdd this
  9. Toni VekovМногопрофилна Болница за Активно Лечение Сърце и Мозък Плевен,България, BulgariaAdd this
  10. Assia KonsoulovaСъвместна онкологична национална мрежа (СОНМ), BulgariaAdd this
  11. Rolando MedeirosInstituto Oncológico Fundación Arturo López Pérez (FALP), ChileAdd this
  12. Wensheng LiuJinshazhou Hospital of Guangzhou University of Chinese Medicine, ChinaAdd this
  13. Carolina WiesnerNational Cancer Institute of Colombia, ColombiaAdd this
  14. Robert ŠeparovićUniversity Hospital for Tumors, Sestre milosrdnice University Hospital Centre, CroatiaAdd this
  15. Ivica BelinaKoalicija udruga u zdravstvu KUZ, CroatiaAdd this
  16. Nikolaos ZamboglouGerman Oncology Center, CyprusAdd this
  17. Panos ErgatoudesΟγκολογικό Κέντρο Τράπεζας Κύπρου, CyprusAdd this
  18. Petr PoloučekMotol University Hospital (MUH), Czech RepublicAdd this
  19. Ladislav DušekInstitute of Biostatistics and Analyses,Faculty of Medicine and Faculty of Science, Masaryk University, Czech RepublicAdd this
  20. Christian SauvrVejle Cancer Centre – The Patients’ Cancer Hospital part of Lillebaelt Hospital, DenmarkAdd this
  21. Jannick BrennumKræftafdelingen Rigshospitalet, DenmarkAdd this
  22. Lisbet Isenbeg RavnCopenhagen Comprehensive Cancer Center (CCCC) Departement for cancer treatment, Herlev and Gentofte Hospital, DenmarkAdd this
  23. Niels Nørgaard PedersenOdense University Hospital, DenmarkAdd this
  24. Lars Dahl PedersenAalborg University Hospital, DenmarkAdd this
  25. Ricco Norman DyhrZealand University Hospital, DenmarkAdd this
  26. Priit PerensTartu University Hospital, EstoniaAdd this
  27. Kristo EriksonNorth Estonia Medical Centre, EstoniaAdd this
  28. Tarmo BaklerEast Tallinn Central Hospital, EstoniaAdd this
  29. Sirkku JyrkkiöTurku University Hospital Cancer Centre, FinlandAdd this
  30. Annika AuranenTAYS Cancer Centre Tampere University Hospital, FinlandAdd this
  31. Arto MannermaaKuopio University Hospital (KUH) Cancer Centre, FinlandAdd this
  32. Juha KorpelainenOulu University Hospital, FinlandAdd this
  33. Tomi P. MäkeläFinnish Cancer Center - FICAN, FinlandAdd this
  34. Frédérique Penault-LlorcaComprehensive Cancer Center Jean Perrin, FranceAdd this
  35. Marc YchouInstitut du Cancer de Montpellier (ICM), FranceAdd this
  36. Pierre Laurent-PuigInstitut du cancer Paris CARPEM AP-HP.Centre-Université Paris Cité, FranceAdd this
  37. Roman RouzierCentre François Baclesse, FranceAdd this
  38. Mario CamponeIntegrated Center for Oncology, FranceAdd this
  39. Renaud de CrevoisierEugène Marquis Cancer Centre, FranceAdd this
  40. Eric Felix LartigauOscar Lambret Center, FranceAdd this
  41. Gérard ZalcmanCancer Institute AP-HP. Nord - Université Paris Cité, FranceAdd this
  42. Pierre VeraCentre Henri Becquerel, FranceAdd this
  43. Jean-Philippe SpanoAssistance Publique – Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université (IUC APHP.SU), FranceAdd this
  44. Yacine MerroucheInstitut Godinot, FranceAdd this
  45. Charles CoutantGeorges-François Leclerc Cancer Center, FranceAdd this
  46. Didier PeiffertInstitut de Cancérologie de Lorraine, FranceAdd this
  47. Pascal HammelCancer Institute – AP-HP. Paris-Saclay University, FranceAdd this
  48. Christophe TournigandAP-HP. Hôpitaux Universitaires Henri-Mondor Cancer Institute, FranceAdd this
  49. Xavier PivotInstitut Strauss, FranceAdd this
  50. Daniel SerinInstitut Sainte Catherine, FranceAdd this
  51. Andreas MackensenBavarian Cancer Research Center (BZKF), GermanyAdd this
  52. Panagiotis KliridesΓενικό Αντικαρκινικό Ογκολογικό Νοσοκομείο Αθηνών «Ο Άγιος Σάββας», GreeceAdd this
  53. Sarantos EfstathopoulosΓενικο Αντικαρκινικο Νοσοκομειο Πειραια Μεταξα, GreeceAdd this
  54. Georgios KapetanakisΕλληνικη Ομοσπονδια Καρκινου - ΕΛΛΟΚ, GreeceAdd this
  55. Krisztina BogosOrszágos Korányi Pulmonológiai Intézet, HungaryAdd this
  56. Vigdís HallgrímsdóttirLandspitali University Hospital, IcelandAdd this
  57. Maeve LoweryTrinity St. James’s Cancer Institute, IrelandAdd this
  58. Anne CoyleBeaumont RCSI Cancer Centre, IrelandAdd this
  59. Joseph MartinHSE West North West, University of Galway Cancer Centre, IrelandAdd this
  60. Dearbhaile CollinsCork University Hospital/University College Cork, IrelandAdd this
  61. David FennellySt Vincent’s UCD Cancer Centre, IrelandAdd this
  62. Jerome CoffeyMater Private Network, IrelandAdd this
  63. Tracey FitzpatrickThe Mater Misericordiae University Hospital, IrelandAdd this
  64. Breda DugganMid-Western Cancer Centre, IrelandAdd this
  65. Ben O'SullivanUniversity Hospital Waterford, IrelandAdd this
  66. Emma BrowneIrish Cancer Society, IrelandAdd this
  67. Giuseppe TonuttiCentro di Riferimento Oncologico di Aviano (CRO), IRCCS, ItalyAdd this
  68. Ilaria PanziniIRCCS Ospedale Policlinico San Martino, ItalyAdd this
  69. Carlo CimbriIEO European Institute of Oncology, ItalyAdd this
  70. Gustavo GalmozziFondazione IRCCS- Istituto Nazionale dei Tumori di Milano, ItalyAdd this
  71. Livio De AngelisRegina Elena National Cancer Institute (IRE), ItalyAdd this
  72. Marco CentenariIRCCS Ospedale San Raffaele (OSR), ItalyAdd this
  73. Davide FornaciariAzienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, ItalyAdd this
  74. Riccardo BuiHumanitas Research Hospital, ItalyAdd this
  75. Andrea AgnelliINOC - Istituto Nazionale Oncologico Candiolo, ItalyAdd this
  76. Luigi CajazzoASST Spedali Civili di Brescia (SCH), ItalyAdd this
  77. Alessandro Delle DonneIstituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, ItalyAdd this
  78. Massimo De FinoIRCCS Centro di Riferimento Oncologico della Basilicata (CROB), ItalyAdd this
  79. Claudio CraccoSacro Cuore - Don Calabria Hospital, ItalyAdd this
  80. Roberto CunsoloMediterranean Institute of Oncology, ItalyAdd this
  81. Mario TaccoliniFondazione Poliambulanza, ItalyAdd this
  82. Alessandro VenturiFondazione IRCCS Policlinico San Matteo, ItalyAdd this
  83. Nicola NormannoIRCCS - Romagna Institute for the Study of Cancer “Dino Amadori” – IRST s.r.l., ItalyAdd this
  84. Daniele PiacentiniFondazione Policlinico Universitario Agostino Gemelli IRCCS, ItalyAdd this
  85. Livio De AngelisSan Gallicano Dermatological Institute, ItalyAdd this
  86. Francesco De LorenzoItalian Federation of Voluntary Associations in Oncology, ItalyAdd this
  87. Maria Rosaria IardinoFondazione The Bridge ETS, ItalyAdd this
  88. Alinta HegmaneRiga East University Hospital, LatviaAdd this
  89. Lauris VidzisPauls Stradins Clinical University Hospital (PSCUH), LatviaAdd this
  90. Ali TaherNaef K Basile Cancer Institute at the American University of Beirut Medical Center, LebanonAdd this
  91. Valdas PečeliūnasNational Cancer Institute, LithuaniaAdd this
  92. Tomas JovaišaVilniaus universiteto ligoninė Santaros klinikos, LithuaniaAdd this
  93. Renaldas JurkevičiusLietuvos sveikatos mokslų universiteto ligoninė Kauno klinikos, LithuaniaAdd this
  94. Audrius ŠimaitisKlaipėda University Hospital, LithuaniaAdd this
  95. Nikolai GoncharenkoInstitut National du Cancer (INC), LuxembourgAdd this
  96. Ruslan BaltagaPublic Health Institution Oncological Institute, MoldovaAdd this
  97. Igor StojkovskiPHI University Clinic for Radiotherapy and Oncology Skopje, North MacedoniaAdd this
  98. Bjørn Atle BjørnbethOslo University Hospital (OUH), NorwayAdd this
  99. Oddbjorn StraumeHelse Bergen - Haukeland University Hospital, NorwayAdd this
  100. Øystein MælandAkershus University Hospital Trust, NorwayAdd this
  101. Giuliana Càrdenas GamarraClínica Oncosalud - AUNA, PeruAdd this
  102. Tomasz MaciejewskiInstitute of Mother and Child, PolandAdd this
  103. Jakub KraszewskiUniversity Clinical Center (UCK) of Medical University of Gdansk, PolandAdd this
  104. Iwona MaroszyńskaPolish Mothers Memorial Hospital Research Institute, PolandAdd this
  105. Julian MalickiGreater Poland Cancer Centre, PolandAdd this
  106. Joanna LorencAidPort Clinical Trial Hospital, PolandAdd this
  107. Maria Margarida Torres OrnelasPortuguese Oncology Institute of Coimbra, PortugalAdd this
  108. Mirela GrosuIași Regional Oncology Institute, RomaniaAdd this
  109. Delia NicoarăCancer Free Future Association, RomaniaAdd this
  110. Ivan S. StilidiФедеральное государственное бюджетное научное учреждение «Российский научный онкологический центр им. Н.Н.Блохина», Russian FederationAdd this
  111. Jasna TrifunovicOncology Institute of Vojvodina, SerbiaAdd this
  112. Miroslav ChovanecBiomedical Research Center of the Slovak Academy of Sciences, SlovakiaAdd this
  113. Helena Isàbal RocaCatalan Institute of Oncology, SpainAdd this
  114. Albert Salazar SolerVall d’Hebron Barcelona Hospital Campus, SpainAdd this
  115. Javier Arcos CampilloHospital Universitario Fundación Jiménez Díaz, SpainAdd this
  116. Manuel Llombart FuertesIVO Foundation, SpainAdd this
  117. Anton Benet CatalàSouthern Catalonia Oncology Institute University Hospital Sant Joan of Reus, SpainAdd this
  118. César Gregorio Muñoz Sánchez-MiguelCentro Integral Oncológico Clara Campal, SpainAdd this
  119. Carmen Martínez de Pancorbo González12 de Octubre University Hospital, SpainAdd this
  120. Rafael Pérez-SantamarinaLa Paz University Hospital, SpainAdd this
  121. Carlos Mingo RodriguezRamon y Cajal University Hospital, SpainAdd this
  122. César Adolfo Gómez DerchHospital Clínico San Carlos, SpainAdd this
  123. Álvaro Bonet PlaHospital Clínico Universitario de Valencia (Departamento de Salud Clínico-Malvarrosa), SpainAdd this
  124. Sonia García de San JoséGregorio Marañón University Hospital, SpainAdd this
  125. Jose Julián Díaz MelguizoLa Princesa University Hospital, SpainAdd this
  126. Julio García PondalUniversity Hospital Puerta de Hierro Majadahonda, SpainAdd this
  127. Adrià Comella CarnicéCampus Sant Pau – Puigvert, SpainAdd this
  128. Jesús Fernández GalánHospital Universitario Virgen de la Victoria, SpainAdd this
  129. José Luis Poveda AndrésHospital Universitario y Politécnico La Fe, SpainAdd this
  130. Luis Ibáñez GadeaDoctor Peset University Hospital, SpainAdd this
  131. Ramón Reyes BoriSpanish Association Against Cancer, SpainAdd this
  132. Patrik RossiKarolinska Comprehensive Cancer Center, SwedenAdd this
  133. Pamela BuchwaldSkåne University Hospital Comprehensive Cancer Centre, SwedenAdd this
  134. Erik JohnssonSahlgrenska University Hospital, SwedenAdd this
  135. Karl LandergrenLinköping Comprehensive Cancer Center, SwedenAdd this
  136. Jonas ClaessonÖrebro Comprehensive Cancer Centre, SwedenAdd this
  137. Pia NäsvallUniversity Hospital of Umeå, SwedenAdd this
  138. Gustaf StormCapio Saint Göran's Hospital, SwedenAdd this
  139. Margareta HaagSwedish Network Against Cancer (NMC), SwedenAdd this
  140. Markus G. ManzComprehensive Cancer Center Zurich (CCCZ), SwitzerlandAdd this
  141. Daniel StaubUniversity Hospital Basel, SwitzerlandAdd this
  142. Sulaiman ShahabuddinThe Aga Khan Hospital, Dar es Salaam, TanzaniaAdd this
  143. R.R.W.J. van der HulstOncoZON Cancer Network, The NetherlandsAdd this
  144. Maurice van den BoschNetherlands Cancer Institute, The NetherlandsAdd this
  145. H.M.W. VerheulErasmus MC Kanker Instituut, The NetherlandsAdd this
  146. R.R.W.J. van der HulstComprehensive Cancer Centre GROW, School for Oncology and & Reproduction, The NetherlandsAdd this
  147. Lukas B. BeenUniversity Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), The NetherlandsAdd this
  148. Rosaline den BlankenRijnstate, The NetherlandsAdd this
  149. Haiko BloemendalRadboudumc Centre for Oncology, The NetherlandsAdd this
  150. Ernst J. KuipersNetherlands Comprehensive Cancer Organisation, The NetherlandsAdd this

The full list is in src/data/universe-lists/oeci-members.json.

Directors of NCI-designated cancer centres

people66 of about 74 (89.2%)

World: One director per NCI-designated centre; the NCI profile pages do not list names, so only the count is external. NCI: Find a Cancer Center, checked on 2026-09-10.

OnCo: People in OnCo whose primary institution is NCI-designated and whose role starts with Director.

The source publishes a total, not a list, so the gap (8) cannot be itemised here. Propose an addition through the new-object form.

KEGG cancer pathway maps

pathways7 of 28 (25%)

World: Maps listed under 'Cancer: overview' and 'Cancer: specific types' in KEGG BRITE br08901 (pathway map hierarchy), via the KEGG REST API. KEGG PATHWAY: Human Diseases, Cancer, checked on 2026-09-10.

OnCo: KEGG maps mapped by hand to at least one OnCo pathway page (src/lib/completeness.ts).

21 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. MicroRNAs in canceroverview mapAdd this
  2. Proteoglycans in canceroverview mapAdd this
  3. Chemical carcinogenesis - receptor activationoverview mapAdd this
  4. Choline metabolism in canceroverview mapAdd this
  5. Colorectal cancerdisease-specific mapAdd this
  6. Pancreatic cancerdisease-specific mapAdd this
  7. Hepatocellular carcinomadisease-specific mapAdd this
  8. Gastric cancerdisease-specific mapAdd this
  9. Gliomadisease-specific mapAdd this
  10. Thyroid cancerdisease-specific mapAdd this
  11. Acute myeloid leukemiadisease-specific mapAdd this
  12. Chronic myeloid leukemiadisease-specific mapAdd this
  13. Basal cell carcinomadisease-specific mapAdd this
  14. Melanomadisease-specific mapAdd this
  15. Renal cell carcinomadisease-specific mapAdd this
  16. Bladder cancerdisease-specific mapAdd this
  17. Prostate cancerdisease-specific mapAdd this
  18. Endometrial cancerdisease-specific mapAdd this
  19. Breast cancerdisease-specific mapAdd this
  20. Small cell lung cancerdisease-specific mapAdd this
  21. Non-small cell lung cancerdisease-specific mapAdd this

Hallmarks of cancer (Hanahan 2022)

pathways14 of 14 (100%)

World: The eight hallmarks and two enabling characteristics of Hanahan and Weinberg (2011) plus the two emerging hallmarks and two enabling characteristics proposed in the 2022 update: fourteen in total. Each is mapped by hand to the OnCo pathway pages that explain it; a hallmark counts as covered when at least one mapped page exists. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery 2022;12(1):31-46, checked on 2026-09-10.

OnCo: Hallmarks with at least one mapped OnCo pathway page.

Every listed item is in OnCo.

Reactome human pathways matching 'cancer'

pathways86 of about 492 (17.5%)

World: Reactome ContentService search for 'cancer', species Homo sapiens, type Pathway; the number of matching pathways. A text search, so approximate. Reactome: pathways matching 'cancer' (human), checked on 2026-09-10.

OnCo: All pathway pages in OnCo (a scale comparison, not a name match).

The source publishes a total, not a list, so the gap (406) cannot be itemised here. Propose an addition through the new-object form.

MEDLINE-indexed journals under the subject Neoplasms

journals31 of 223 (13.9%)

World: E-utilities esearch on the NLM Catalog for 'neoplasms[st] AND currentlyindexed[All]' (the MEDLINE broad subject term for cancer journals), then esummary for titles and ISSNs. NLM Catalog: journals currently indexed for MEDLINE, broad subject term Neoplasms, checked on 2026-09-10.

OnCo: NLM journals matched to an OnCo journal by ISSN, title or MEDLINE abbreviation.

192 missing, first 150 shown. Each “Add this” opens the new-object issue form, prefilled.
  1. Acta oncologicaActa Oncol, SwedenAdd this
  2. Advances in cancer researchAdv Cancer Res, United StatesAdd this
  3. American journal of clinical oncologyAm J Clin Oncol, United StatesAdd this
  4. American Society of Clinical Oncology educational bookAm Soc Clin Oncol Educ Book, United StatesAdd this
  5. Analytical cellular pathology (Amsterdam)Anal Cell Pathol (Amst), United StatesAdd this
  6. Annals of surgical oncologyAnn Surg Oncol, United StatesAdd this
  7. Anticancer researchAnticancer Res, GreeceAdd this
  8. Asia-Pacific journal of clinical oncologyAsia Pac J Clin Oncol, AustraliaAdd this
  9. Asian Pacific journal of cancer prevention : APJCPAsian Pac J Cancer Prev, ThailandAdd this
  10. Biochimica et biophysica acta. Reviews on cancerBiochim Biophys Acta Rev Cancer, NetherlandsAdd this
  11. Blood cancer discoveryBlood Cancer Discov, United StatesAdd this
  12. Blood cancer journalBlood Cancer J, United StatesAdd this
  13. BMC cancerBMC Cancer, EnglandAdd this
  14. Brain tumor pathologyBrain Tumor Pathol, JapanAdd this
  15. Breast cancer : the journal of the Japanese Breast Cancer SocietyBreast Cancer, JapanAdd this
  16. Breast cancer research : BCRBreast Cancer Res, EnglandAdd this
  17. Breast cancer research and treatmentBreast Cancer Res Treat, NetherlandsAdd this
  18. Bulletin du cancerBull Cancer, FranceAdd this
  19. Cancer biology & medicineCancer Biol Med, ChinaAdd this
  20. Cancer biology & therapyCancer Biol Ther, United StatesAdd this
  21. Cancer biomarkers : section A of Disease markersCancer Biomark, United StatesAdd this
  22. Cancer biotherapy & radiopharmaceuticalsCancer Biother Radiopharm, United StatesAdd this
  23. Cancer causes & control : CCCCancer Causes Control, NetherlandsAdd this
  24. Cancer chemotherapy and pharmacologyCancer Chemother Pharmacol, GermanyAdd this
  25. Cancer communicationsCancer Commun (Lond), United StatesAdd this
  26. Cancer control : journal of the Moffitt Cancer CenterCancer Control, United StatesAdd this
  27. Cancer cytopathologyCancer Cytopathol, United StatesAdd this
  28. Cancer epidemiologyCancer Epidemiol, NetherlandsAdd this
  29. Cancer gene therapyCancer Gene Ther, EnglandAdd this
  30. Cancer geneticsCancer Genet, United StatesAdd this
  31. Cancer genomics & proteomicsCancer Genomics Proteomics, GreeceAdd this
  32. Cancer imaging : the official publication of the International Cancer Imaging SocietyCancer Imaging, EnglandAdd this
  33. Cancer immunology, immunotherapy : CIICancer Immunol Immunother, GermanyAdd this
  34. Cancer investigationCancer Invest, EnglandAdd this
  35. Cancer lettersCancer Lett, IrelandAdd this
  36. Cancer medicineCancer Med, United StatesAdd this
  37. Cancer metastasis reviewsCancer Metastasis Rev, NetherlandsAdd this
  38. Cancer nursingCancer Nurs, United StatesAdd this
  39. Cancer prevention researchCancer Prev Res (Phila), United StatesAdd this
  40. Cancer radiothérapie : journal de la Société française de radiothérapie oncologiqueCancer Radiother, FranceAdd this
  41. Cancer reportsCancer Rep (Hoboken), United StatesAdd this
  42. Cancer research and treatmentCancer Res Treat, Korea (South)Add this
  43. Cancer research communicationsCancer Res Commun, United StatesAdd this
  44. Cancer scienceCancer Sci, EnglandAdd this
  45. Cancer treatment and researchCancer Treat Res, United StatesAdd this
  46. Cancer treatment and research communicationsCancer Treat Res Commun, EnglandAdd this
  47. Cancer treatment reviewsCancer Treat Rev, NetherlandsAdd this
  48. CarcinogenesisCarcinogenesis, EnglandAdd this
  49. Cellular oncologyCell Oncol (Dordr), NetherlandsAdd this
  50. Chinese clinical oncologyChin Clin Oncol, ChinaAdd this
  51. Clinical & experimental metastasisClin Exp Metastasis, NetherlandsAdd this
  52. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoClin Transl Oncol, ItalyAdd this
  53. Clinical advances in hematology & oncology : H&OClin Adv Hematol Oncol, United StatesAdd this
  54. Clinical breast cancerClin Breast Cancer, United StatesAdd this
  55. Clinical colorectal cancerClin Colorectal Cancer, United StatesAdd this
  56. Clinical genitourinary cancerClin Genitourin Cancer, United StatesAdd this
  57. Clinical journal of oncology nursingClin J Oncol Nurs, United StatesAdd this
  58. Clinical lung cancerClin Lung Cancer, United StatesAdd this
  59. Clinical lymphoma, myeloma & leukemiaClin Lymphoma Myeloma Leuk, United StatesAdd this
  60. Clinical oncology : a journal of the Royal College of RadiologistsClin Oncol (R Coll Radiol), EnglandAdd this
  61. CNS oncologyCNS Oncol, EnglandAdd this
  62. Critical reviews in oncogenesisCrit Rev Oncog, United StatesAdd this
  63. Critical reviews in oncology/hematologyCrit Rev Oncol Hematol, NetherlandsAdd this
  64. Current cancer drug targetsCurr Cancer Drug Targets, NetherlandsAdd this
  65. Current hematologic malignancy reportsCurr Hematol Malig Rep, United StatesAdd this
  66. Current oncologyCurr Oncol, SwitzerlandAdd this
  67. Current oncology reportsCurr Oncol Rep, United StatesAdd this
  68. Current opinion in oncologyCurr Opin Oncol, United StatesAdd this
  69. Current problems in cancerCurr Probl Cancer, United StatesAdd this
  70. Current treatment options in oncologyCurr Treat Options Oncol, United StatesAdd this
  71. Endocrine-related cancerEndocr Relat Cancer, EnglandAdd this
  72. Esophagus : official journal of the Japan Esophageal SocietyEsophagus, JapanAdd this
  73. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)Eur J Cancer Prev, EnglandAdd this
  74. European journal of oncology nursing : the official journal of European Oncology Nursing SocietyEur J Oncol Nurs, ScotlandAdd this
  75. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyEur J Surg Oncol, EnglandAdd this
  76. European thyroid journalEur Thyroid J, EnglandAdd this
  77. Experimental oncologyExp Oncol, UkraineAdd this
  78. Expert review of anticancer therapyExpert Rev Anticancer Ther, EnglandAdd this
  79. Familial cancerFam Cancer, NetherlandsAdd this
  80. Future oncologyFuture Oncol, EnglandAdd this
  81. Gan to kagaku ryoho. Cancer & chemotherapyGan To Kagaku Ryoho, JapanAdd this
  82. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationGastric Cancer, JapanAdd this
  83. Genes, chromosomes & cancerGenes Chromosomes Cancer, United StatesAdd this
  84. Head & neckHead Neck, United StatesAdd this
  85. Head and neck pathologyHead Neck Pathol, United StatesAdd this
  86. Hematological oncologyHematol Oncol, EnglandAdd this
  87. Hematology/oncology and stem cell therapyHematol Oncol Stem Cell Ther, IndiaAdd this
  88. Hematology/oncology clinics of North AmericaHematol Oncol Clin North Am, United StatesAdd this
  89. In vivoIn Vivo, GreeceAdd this
  90. Indian journal of cancerIndian J Cancer, IndiaAdd this
  91. Integrative cancer therapiesIntegr Cancer Ther, United StatesAdd this
  92. International journal of cancerInt J Cancer, United StatesAdd this
  93. International journal of clinical oncologyInt J Clin Oncol, JapanAdd this
  94. International journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyInt J Gynecol Cancer, United StatesAdd this
  95. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupInt J Hyperthermia, EnglandAdd this
  96. International journal of oncologyInt J Oncol, GreeceAdd this
  97. Japanese journal of clinical oncologyJpn J Clin Oncol, EnglandAdd this
  98. JCO clinical cancer informaticsJCO Clin Cancer Inform, United StatesAdd this
  99. JCO global oncologyJCO Glob Oncol, United StatesAdd this
  100. JMIR cancerJMIR Cancer, CanadaAdd this
  101. JNCI cancer spectrumJNCI Cancer Spectr, EnglandAdd this
  102. Journal of adolescent and young adult oncologyJ Adolesc Young Adult Oncol, United StatesAdd this
  103. Journal of breast imagingJ Breast Imaging, United StatesAdd this
  104. Journal of cachexia, sarcopenia and muscleJ Cachexia Sarcopenia Muscle, GermanyAdd this
  105. Journal of cancer education : the official journal of the American Association for Cancer EducationJ Cancer Educ, EnglandAdd this
  106. Journal of cancer policyJ Cancer Policy, EnglandAdd this
  107. Journal of cancer research and clinical oncologyJ Cancer Res Clin Oncol, GermanyAdd this
  108. Journal of cancer research and therapeuticsJ Cancer Res Ther, IndiaAdd this
  109. Journal of cancer survivorship : research and practiceJ Cancer Surviv, United StatesAdd this
  110. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and CancerJ Environ Pathol Toxicol Oncol, United StatesAdd this
  111. Journal of experimental & clinical cancer research : CRJ Exp Clin Cancer Res, EnglandAdd this
  112. Journal of gastric cancerJ Gastric Cancer, Korea (South)Add this
  113. Journal of gastrointestinal cancerJ Gastrointest Cancer, United StatesAdd this
  114. Journal of geriatric oncologyJ Geriatr Oncol, NetherlandsAdd this
  115. Journal of gynecologic oncologyJ Gynecol Oncol, Korea (South)Add this
  116. Journal of hematology & oncologyJ Hematol Oncol, EnglandAdd this
  117. Journal of immunotherapyJ Immunother, United StatesAdd this
  118. Journal of mammary gland biology and neoplasiaJ Mammary Gland Biol Neoplasia, United StatesAdd this
  119. Journal of medical imaging and radiation oncologyJ Med Imaging Radiat Oncol, AustraliaAdd this
  120. Journal of neuro-oncologyJ Neurooncol, United StatesAdd this
  121. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersJ Oncol Pharm Pract, EnglandAdd this
  122. Journal of pediatric hematology/oncologyJ Pediatr Hematol Oncol, United StatesAdd this
  123. Journal of pediatric hematology/oncology nursingJ Pediatr Hematol Oncol Nurs, United StatesAdd this
  124. Journal of psychosocial oncologyJ Psychosoc Oncol, United StatesAdd this
  125. Journal of radiation researchJ Radiat Res, EnglandAdd this
  126. Journal of registry managementJ Registry Manag, United StatesAdd this
  127. Journal of surgical oncologyJ Surg Oncol, United StatesAdd this
  128. Journal of the Egyptian National Cancer InstituteJ Egypt Natl Canc Inst, EnglandAdd this
  129. Journal of the National Cancer Institute. MonographsJ Natl Cancer Inst Monogr, United StatesAdd this
  130. Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnostiKlin Onkol, Czech RepublicAdd this
  131. Leukemia & lymphomaLeuk Lymphoma, United StatesAdd this
  132. Leukemia researchLeuk Res, EnglandAdd this
  133. Lung cancer : journal of the International Association for the Study of Lung CancerLung Cancer, IrelandAdd this
  134. Magyar onkologiaMagy Onkol, HungaryAdd this
  135. Medical oncologyMed Oncol, United StatesAdd this
  136. Melanoma researchMelanoma Res, EnglandAdd this
  137. Molecular cancerMol Cancer, EnglandAdd this
  138. Molecular cancer research : MCRMol Cancer Res, United StatesAdd this
  139. Molecular carcinogenesisMol Carcinog, United StatesAdd this
  140. Molecular oncologyMol Oncol, United StatesAdd this
  141. NAR cancerNAR Cancer, EnglandAdd this
  142. Neoplasia : an international journal for oncology researchNeoplasia, United StatesAdd this
  143. NeoplasmaNeoplasma, SlovakiaAdd this
  144. Nutrition and cancerNutr Cancer, United StatesAdd this
  145. OncogeneOncogene, EnglandAdd this
  146. OncoimmunologyOncoimmunology, United StatesAdd this
  147. OncologyOncology (Williston Park), United StatesAdd this
  148. OncologyOncology, SwitzerlandAdd this
  149. Oncology nursing forumOncol Nurs Forum, United StatesAdd this
  150. Oncology reportsOncol Rep, GreeceAdd this

The full list is in src/data/universe-lists/nlm-oncology-journals.json.

100 most-cited oncology works (OpenAlex)

key papers9 of 100 (9%)

World: OpenAlex works filtered to primary_topic.subfield = Oncology (2730), sorted by citation count, first 100. OpenAlex: most-cited works, subfield Oncology, checked on 2026-09-10.

OnCo: Works matched to an OnCo key paper by DOI.

91 missing. Each “Add this” opens the new-object issue form, prefilled.
  1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021, 114,179 citationsAdd this
  2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2018, 88,114 citationsAdd this
  3. Global cancer statistics2011, 55,097 citationsAdd this
  4. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016, 30,920 citationsAdd this
  5. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 20122014, 29,167 citationsAdd this
  6. Global cancer statistics, 20122015, 27,419 citationsAdd this
  7. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024, 25,401 citationsAdd this
  8. Cancer statistics, 20192019, 21,028 citationsAdd this
  9. Global Cancer Statistics, 20022005, 18,425 citationsAdd this
  10. Cancer statistics, 20222022, 18,328 citationsAdd this
  11. Cancer statistics in China, 20152016, 18,017 citationsAdd this
  12. Cancer Statistics, 20212021, 17,448 citationsAdd this
  13. AJCC Cancer Staging Manual2016, 17,438 citationsAdd this
  14. Cancer statistics, 20182018, 17,042 citationsAdd this
  15. Cancer statistics, 20232023, 16,971 citationsAdd this
  16. Cancer statistics, 20162016, 16,186 citationsAdd this
  17. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology1993, 16,182 citationsAdd this
  18. New Guidelines to Evaluate the Response to Treatment in Solid Tumors2000, 15,763 citationsAdd this
  19. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017, 15,290 citationsAdd this
  20. Inflammation and cancer2002, 15,212 citationsAdd this
  21. Cancer statistics, 20172017, 14,991 citationsAdd this
  22. Dermatologist-level classification of skin cancer with deep neural networks2017, 14,352 citationsAdd this
  23. The blockade of immune checkpoints in cancer immunotherapy2012, 13,936 citationsAdd this
  24. Cancer Statistics, 20102010, 12,621 citationsAdd this
  25. Cancer statistics, 20152015, 11,933 citationsAdd this
  26. Cancer statistics, 20132013, 11,915 citationsAdd this
  27. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987, 11,808 citationsAdd this
  28. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001, 11,600 citationsAdd this
  29. Cancer statistics, 20142014, 11,580 citationsAdd this
  30. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer2004, 11,028 citationsAdd this
  31. Immunity, Inflammation, and Cancer2010, 10,848 citationsAdd this
  32. Cancer statistics, 20122012, 10,723 citationsAdd this
  33. Prospective identification of tumorigenic breast cancer cells2003, 10,404 citationsAdd this
  34. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016, 10,268 citationsAdd this
  35. Cancer Statistics, 20082008, 10,214 citationsAdd this
  36. The basics of epithelial-mesenchymal transition2009, 10,213 citationsAdd this
  37. Stem cells, cancer, and cancer stem cells2001, 9,756 citationsAdd this
  38. Cancer Statistics, 20092009, 9,730 citationsAdd this
  39. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015, 9,535 citationsAdd this
  40. Cancer statistics, 20242024, 9,418 citationsAdd this
  41. Synthesis, structure, and spectroscopic properties of copper( II ) compounds containing nitrogen–sulphur donor ligands; the crystal and molecular structure of aqua[1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper( II ) perchlorate1984, 9,417 citationsAdd this
  42. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells2008, 8,774 citationsAdd this
  43. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015, 8,621 citationsAdd this
  44. Cancer Incidence in Five Continents1970, 8,540 citationsAdd this
  45. WAF1, a potential mediator of p53 tumor suppression1993, 8,406 citationsAdd this
  46. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates2002, 8,339 citationsAdd this
  47. Molecular mechanisms of epithelial–mesenchymal transition2014, 8,277 citationsAdd this
  48. Microenvironmental regulation of tumor progression and metastasis2013, 8,241 citationsAdd this
  49. p53 Mutations in Human Cancers1991, 8,119 citationsAdd this
  50. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer2015, 8,014 citationsAdd this
  51. Cell Signaling by Receptor Tyrosine Kinases2010, 7,965 citationsAdd this
  52. A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS1909, 7,909 citationsAdd this
  53. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer2011, 7,894 citationsAdd this
  54. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods2018, 7,811 citationsAdd this
  55. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults2003, 7,745 citationsAdd this
  56. p53, the Cellular Gatekeeper for Growth and Division1997, 7,741 citationsAdd this
  57. Inflammation and cancer: back to Virchow?2001, 7,737 citationsAdd this
  58. Cancer Statistics, 20072007, 7,487 citationsAdd this
  59. Identification of human brain tumour initiating cells2004, 7,449 citationsAdd this
  60. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial2010, 7,382 citationsAdd this
  61. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States2014, 7,334 citationsAdd this
  62. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche2009, 7,307 citationsAdd this
  63. Pancreatic Cancer2000, 7,246 citationsAdd this
  64. Oncology Meets Immunology: The Cancer-Immunity Cycle2013, 7,066 citationsAdd this
  65. Untangling the ErbB signalling network2001, 7,024 citationsAdd this
  66. Cancer immunotherapy using checkpoint blockade2018, 6,904 citationsAdd this
  67. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989, 6,868 citationsAdd this
  68. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine2013, 6,797 citationsAdd this
  69. Factors associated with COVID-19-related death using OpenSAFELY2020, 6,782 citationsAdd this
  70. PD-1 blockade induces responses by inhibiting adaptive immune resistance2014, 6,721 citationsAdd this
  71. Epithelial–mesenchymal transitions in tumour progression2002, 6,707 citationsAdd this
  72. Surfing the p53 network2000, 6,634 citationsAdd this
  73. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells2017, 6,629 citationsAdd this
  74. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial2015, 6,576 citationsAdd this
  75. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome2006, 6,549 citationsAdd this
  76. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion2011, 6,500 citationsAdd this
  77. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response2006, 6,446 citationsAdd this
  78. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 20152016, 6,333 citationsAdd this
  79. The Immune Landscape of Cancer2018, 6,309 citationsAdd this
  80. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries2018, 6,304 citationsAdd this
  81. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer2015, 6,294 citationsAdd this
  82. Understanding the tumor immune microenvironment (TIME) for effective therapy2018, 6,289 citationsAdd this
  83. Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins1994, 6,132 citationsAdd this
  84. CDK inhibitors: positive and negative regulators of G1-phase progression1999, 6,131 citationsAdd this
  85. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer2004, 6,108 citationsAdd this
  86. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.1993, 6,084 citationsAdd this
  87. Cancer Incidence in Five Continents1966, 6,018 citationsAdd this
  88. Pembrolizumab versus Ipilimumab in Advanced Melanoma2015, 5,928 citationsAdd this
  89. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.1997, 5,917 citationsAdd this
  90. Cancer statistics for the year 2020: An overview2021, 5,818 citationsAdd this
  91. TIMER2.0 for analysis of tumor-infiltrating immune cells2020, 5,784 citationsAdd this

NCI Dictionary of Cancer Terms

terms605 of 9,416 (6.4%)

World: The term count returned by the NCI glossary API for the English patient dictionary. NCI Dictionary of Cancer Terms, checked on 2026-09-10.

OnCo: All glossary terms in OnCo (a scale comparison, not a term match).

The source publishes a total, not a list, so the gap (8,811) cannot be itemised here. Propose an addition through the new-object form.

Kinds OnCo defines itself

These are OnCo's own taxonomy. There is no external list of fronts, technologies, pairings, roadmaps, ideas, bottlenecks or collections to count against, so no completeness is claimed; the number is the corpus count.

See also the corpus health gauges (record-level completeness), gaps to fill, and open data sources.